Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients

Clinical and Experimental Immunology

Volumn 119, Issue 2, 2000, Pages 323-327

  Otsuki, T ^a   Tomokuni, A ^a   Sakaguchi, H ^a   Aikoh, T ^a   Matsuki, T ^a   Isozaki, Y ^a   Hyodoh, F ^a   Ueki, H ^a   Kusaka, M ^b   Kita, S ^a   Ueki, A ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Kusaka Hospital   (Japan)

Author keywords

Apoptosis; DcR3; RT PCR; Silicosis; Soluble Fas

Indexed keywords

FAS ANTIGEN; LIGAND;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; LIGAND BINDING; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; RECEPTOR GENE; RESPIRATORY TRACT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SILICOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION; GENES; HUMANS; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RECEPTORS, CELL SURFACE; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SILICOSIS;

EID: 0033979307     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01132.x     Document Type: Article

References (36)

1. Itoh N, Yonehara S, Ishii A et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66:233-43.
2. Itoh N, Nagata SA. Novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993; 268:10932-7.
3. Cohen PL, Eisenberg RA. The lpr and gld genes in systemic autoimmunity: Life and death in the Fas lane. Immunol Today 1992; 13:427-8.
4. Mountz JD, Wu J, Cheng J et al. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum 1994; 37:1415-20.
5. Rose LM, Latchman DS, Isenberg DA. Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: A review. Br J Rheumatol 1997; 36:158-63.
6. Watanabe-Fukunaga R, Brannan CI, Copeland NG et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:314-7.
7. Nagata S. Mutations in the Fas antigen gene in lpr mice. Semin Immunol 1994; 6:3-8.
8. Takahashi T, Tanaka M, Brannan CI et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76:969-76.
9. Suda T, Nagata S. Why do defects in the Fas-Fas ligand system cause autoimmunity? J Allergy Clin Immunol 1997; 100:S97-101.
10. Nagata S. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: A lesson from the mouse model. J Hum Genet 1998; 43:2-8.
11. Fisher GH, Rosenberg FJ, Straus SE et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81:935-46.
12. Puck JM, Sneller MC. ALPS: An autoimmune human lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Semin Immunol 1997; 9:77-84.
13. Jackson CE, Fischer RE, Hsu AP et al. Autoimmune lymphoproliferative syndrome with defective Fas: Genotype influences penetrance. Am J Hum Genet 1999; 64:1002-14.
14. Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263:1759-62.
15. Liu C, Cheng J, Mountz JD. Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. Biochem J 1995; 310:957-63.
16. Cascino I, Papoff G, Eramo A et al. Soluble Fas/Apo-1 splicing variants and apoptosis. Front Biosci 1996; 1:d12-8.
17. Tokano Y, Miyake S, Kayagaki N et al. Soluble Fas molecule in the serum of patients with systemic lupus erythematosus. J Clin Immunol 1996; 16:261-5.
18. Jodo S, Kobayashi S, Kayagaki N et al. Serum levels of soluble Fas/ APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 1997; 107:89-95.
19. Nozawa K, Kayagaki N, Tokano Y et al. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 1997; 40:1126-9.
20. Knipping E, Debatin KM, Stricker K et al. Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood 1995; 85:1562-9.
21. Pitti RM, Marsters SA, Lawrence DA et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396:699-703.
22. Green DR. Apoptosis. Death deceiver. Nature 1998; 396:629-30.
23. Dinu IV, Roth L. Contributions to the autoimmune pathogeny of silicosis. Rom Med Rev 1966; 20:26-8.
24. Uber CL, McReynolds RA. Immunotoxicology of silica. Crit Rev Toxicol 1982; 10:303-19.
25. Steenland K, Goldsmith DF. Silica exposure and autoimmune diseases. Am J Ind Med 1995; 28:603-8.
26. Haustein UF, Anderegg U. Silica induced scleroderma - Clinical and experimental aspects. J Rheumatol 1998; 25:1917-26.
27. Rosenman KD, Moore-Fuller M, Reilly MJ. Connective tissue disease and silicosis. Am J Ind Med 1999; 35:375-81.
28. Haustein UF. Silica-induced lupus erythematosus. Acta Derm Venereol 1998; 78:73-4.
29. Tomokuni A, Aikoh T, Matsuki T et al. Elevated soluble Fas/Apo-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Clin Exp Immunol 1997; 110:303-9.
30. Tomokuni A, Aikoh T, Matsuki T et al. Elevated soluble Fas levels in patients with silicosis. In: Chiyotani K, Hosoda Y, Aizawa Y, eds. Advances in the Prevention of Occupational Respiratory Diseases (Excerpta Medica International Congress Series ICS 1153). Amsterdam: Elsevier Science, 1998:931-6.
31. Otsuki T, Sakaguchi H, Tomokuni A et al. Soluble Fas mRNA is dominantly expressed in cases with silicosis. Immunol 1998; 94:258-62.
32. Otsuki T, Tomokuni A, Sakaguchi H et al. Soluble Fas message is dominantly expressed in cases with silicosis. In: Chiyotani K, Hosoda Y, Aizawa Y, eds. Advances in the Prevention of Occupational Respiratory Diseases (Excerpta Medica International Congress Series ICS 1153). Amsterdam: Elsevier Science, 1998:896-900.
33. Hamzaoui K, Hamzaoui A, Zakraoui L et al. Levels of soluble Fas/ APO-1 in patients with Behçet's disease. Med Inflamm 1998; 7:111-4.
34. Fujihara T, Takeuchi T, Tsubota K et al. Serum soluble Fas/Apo-1 is increased in patients with primary Sjögren's syndrome. Clin Rheumatol 1998; 17:496-9.
35. Matute-Bello G, Liles WC, Steinberg KP, Kiener PA, Mongovin S, Chi EY, Jonas M, Martin TR. Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury. J Immunol 1999; 163:2217-25.
36. Kuwano K, Hagimoto N, Kawasaki M et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999; 104:13-9.